Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Sugammadex and Neostigmine on Optic Nerve Sheath Diameter During Extubation
NCT07666984Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
- Sponsor
- Cukurova University
- Conditions
- neuromuscular blockade (NMB)
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex and neostigmine in neuromuscular blockade (NMB) (2 arms), sponsored by Cukurova University. Primary endpoint: Change in average optic nerve sheath diameter. Started Jun 2026; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Group S
Sugammadex 2 mg/kg IV single bolus dose
Group N
Neostigmine 0.05 mg/kg IV + Atropine 0.02 mg/kg IV single bolus dose
03
Who it enrols
Adults aged 18-65 with ASA physical status 1-2 scheduled for elective surgery in the supine position, excluding those with significant organ failure, brain/eye/cardiovascular/neurosurgery, increased intracranial pressure, or laparoscopic surgeries.
04
Endpoints
Primary
Change in average optic nerve sheath diameter
Secondary
Blood Pressure
Postoperative nausea and vomiting
Beyond the preview
Go deeper on NCT07666984.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07666984.